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On April 22, 2004, the STS/AATS Committee/Workforce
for the Assessment of New Technology (Appendix 1) or-
ganized a workshop on PHVT. Included were representa-
tives from the STS, the AATS, the ACC, and SCAI. Also in
attendance were representatives from the FDA’s Division of
Cardiovascular Devices, Circulatory Support and Prosthetic
Devices Branch, CMS, and industry representatives (Ap-
pendix 2). Clinical aspects of PHVT were initially ad-
dressed in small groups with representatives from each of
the constituencies followed by a summary report and dis-
cussion amongst the entire group. All participants of the
workshop and writing group members completed a disclo-
sure questionnaire documenting all outside relationships
that might be perceived as real or potential conflicts of
interest.1 Current crucial issues addressed were: 1) trial
design, 2) control groups, 3) end points for assessment, 4)
rate of technological change, 5) institutional and investiga-
tor requirements, and 6) safety. Consideration of these is-
sues is undertaken with the acknowledgement that for most
patients with heart valve disease, open cardiac surgical
procedures provide an established form of treatment.
Background
For decades, percutaneous interventional therapy has been
an option for patients with pulmonic,2-4 mitral,5,6 and aortic
valvular disease.7,8 For selected patients with pulmonic or
mitral stenosis, percutaneous valvuloplasty is the treatment
of choice.9,10 For patients with calcific aortic stenosis, bal-
loon aortic valvuloplasty (BAV)11,12 has been used as a
bridge to aortic valve replacement as noted by the current
ACC/American Heart Association (AHA) guidelines.13
Hospital mortality for BAV varies from 3.5% to 13.5%, and
as many as 25% of the patients have at least one serious
complication.14 The durability of BAV is limited. There-
fore, open aortic valve replacement remains the definitive
therapy for aortic stenosis in patients who are viable candi-
dates for surgery.
Currently, multiple new concepts for the percutaneous
treatment of valvular heart disease are under evaluation in a
variety of stages from bench testing to early clinical trials.15
Most involve either mitral valve repair via annular or leaflet
manipulation, or percutaneous valve insertion for pulmonic
or aortic valve disease. Using a stent-based valve,16,17 per-
cutaneous pulmonary valve insertion has been successfully
carried out in more than 60 cases, primarily outside the
U.S., usually for the treatment of conduit stenosis.18 How-
ever, late follow-up is limited and future trials will need to
focus on the issues of patient selection with degenerated
conduits, durability and the inability of the device to grow.
Although percutaneous aortic valve insertion has been car-
ried out on a compassionate use for extremely high-risk
patients,19,20 significant para-valvular regurgitation and
The Journal of Thoraciearly mortality characterize the experience thus far.21 Cur-
rently, there are no approved percutaneous aortic valve
devices in the U.S.
The goal of the following discussion is to provide a
framework for clinical research directed at further testing of
PHVT.
General Guidelines Regarding
Clinical Trial Design for PHVT
The testing of new medical technology usually begins with
bench testing (in vitro) and in vivo animal testing, followed
by clinical investigation. Initial clinical investigation begins
with a feasibility study: a small, unblinded, and uncon-
trolled trial designed to test safety. Following the feasibility
trials, a larger, prospective, controlled trial is performed to
evaluate both safety and efficacy (Pivotal trial). The most
rigorous design for establishing the safety and effectiveness
of new technology is the controlled, randomized trial. It is
the consensus of the participants of the Workshop that no
adequate historical controls exists for the evaluation of
PHVT sufficient to eliminate the influence of confounding
variables. Therefore, randomized controlled trials are nec-
essary to evaluate safety and efficacy properly for these
devices.
At each institution participating in clinical trials, the
study team should include at least an interventionalist, a
cardiac surgeon, a non-interventional clinical investigator
charged with monitoring patient welfare, and an echocardi-
ographer. All members of the study team should be charged
with ensuring proper patient selection to achieve safety and
objectivity. Furthermore, such collaborative interaction will
aid trial completion and, it is hoped, lead to improvement in
device placement, function, and assessment.
Use of PHVT requires skill sets independent of the
operator’s base discipline, and specific training should be
required before engaging in any percutaneous valve proce-
dure. Those individuals eligible for the procedural training
should be confined to experienced interventionalists and
surgeons. Feasibility studies in adults should be restricted to
a small number of high-volume cardiology and cardiac
surgery programs where at least 100 to 150 surgical valve
operations per year are performed.22 Participating cardiac
surgeons should perform a minimum of 40 to 50 valve
repairs or replacements annually.23 In addition, the sur-
geon’s valve experience should be specific for the device
under consideration (i.e., a surgeon with a large volume of
aortic valve replacement and minimal mitral valve repair
would only qualify for an aortic device study). Although
most interventionalists are likely to be cardiologists, or
rarely interventional radiologists, surgeons with appropriate
training in percutaneous procedures may directly partici-
pate, in addition to providing patient selection, guidance,
and back-up services. Interventionalists should perform at
least 100 percutaneous procedures each year, and have
c and Cardiovascular Surgery ● Volume 129, Number 5 971
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PHVT (e.g., trans-septal and/or coronary sinus access tech-
niques) and with the assessment and management of valvu-
lar heart disease.24-26 Clinical trials should also be limited to
centers with a proven track record of close collaboration
between the aforementioned disciplines and experience in
trials.
A major problem with all new devices is how to evaluate
a first-generation product against the established “gold stan-
dard,” in this case the open cardiac surgical procedure. How
should a new device that avoids cardiac surgery but perhaps
is less effective—especially initially—be best evaluated?
At the design stage of a clinical trial it is essential to state
clearly the purpose of the study and the specific hypothesis
to be evaluated.27 Randomized controlled trial designs can
be broadly viewed as evaluating the superiority or non-
inferiority (clinical equivalence) of the test arm with regard
to effectiveness. Critical differences exist between these two
approaches, which affect sample size, study feasibility, and
credibility of conclusions.28 It is important to point out that
it is statistically, and practically, impossible to demonstrate
equivalence between two treatment arms, as some differ-
ences are always likely to exist. Therefore, a “clinically
acceptable” difference (“delta”) between the two treatment
arms must be specified at the outset and the null hypothesis
constructed such that its rejection supports the claim of
non-inferiority (Table 1).
Sample size estimation would be most appropriately
determined by power calculations for the specific end point
and study results published in the literature. Study end
points should be chosen that can be assessed objectively by:
1) creating clear criteria for the outcome, 2) collecting the
necessary documentation, and 3) having independent core
laboratories, blinded to the treatment assignment, adjudicate
the cases whenever possible. Meaningful outcome measure-
ments could include components such as death, myocardial
infarction, need for surgical repair (including the need for
valve replacement when repair was the preoperative intent),
stroke or embolic events, hemodynamic deterioration, ejec-
tion fraction, measures of reverse remodeling, valvular re-
TABLE 1. Randomized controlled trial designs
Trial design type
Null hypothesis for
effectiveness
Alternate
hypothesis for
effectiveness
Superiority Treatment A success
rate  treatment B
rate
Treatment A success
rate  treatment B
rate
Non-inferiority Treatment A success
rate  treatment B
rate  “delta”
Treatment A success
rate  treatment B
rate  “delta”gurgitation, endocarditis, hemolysis, and functional testing.
972 The Journal of Thoracic and Cardiovascular Surgery ● MayAlthough the timing of end point measurements was dis-
cussed at the Workshop, the consensus was that it is too
early in PHVT development to answer this question.
Finally, in any trial designed to evaluate an intervention,
“crossovers” are likely to occur. Crossover patients can be
analyzed using several methods, including “intent to treat,”
“as treated,” and “per protocol”.29,30 In addition, a large
amount of missing end point data can make interpretation of
trial results difficult and threaten the success of the trial.
Every effort should be made to collect all data specified in
the trial. Additionally, the importance of a knowledgeable
and active Data Safety and Monitoring Board cannot be
overemphasized. This board should be independent of the
investigators, of the company sponsoring the trial, and of
any contracted data analysis organizations involved in the
trial.
Percutaneous Mitral Valve
Repair (PMVR) for Mitral Regurgitation
The pathophysiologic triad describing mitral regurgitation
(MR) is composed of etiology (cause of the disease), valve
lesions (resulting from the disease), and valve dysfunction
(resulting from the lesion).31 These distinctions are relevant
because long-term prognosis depends on etiology, whereas
surgical treatment strategy—and future PMVR—depends
on valve dysfunctions and lesions. Mild to moderate MR is
seen in approximately 20% of the general population.32,33
The most common causes of MR in Western countries are
degenerative, ischemic, and dilated cardiomyopathy.34
The STS National Adult Cardiac Surgery Database 2003
notes a countrywide mortality for first time elective mitral
valve repair of 2.5% (males) to 3.9% (females), and for
mitral valve surgery combined with coronary artery bypass
these figures are 6.1% (males) to 12.2% (females), respec-
tively.35 Patients undergoing reoperation are also at in-
creased risk.36 Mitral valve repair is considered superior to
mitral valve replacement because of lower operative mor-
tality, improved late survival, a reduced risk of endocarditis,
fewer thromboembolic complications, and better preserva-
tion of left ventricular function.37-42 However, the majority
of mitral valve operations done in the U.S. in 2003 remained
mitral valve replacement.43 Individual surgeon experience
remains the key factor in predicting the likelihood of mitral
valve repair or replacement for any given patient.
To discuss patient selection for PMVR for MR and to
consider comparative outcomes with surgical approaches, it
is possible to consider two classifications: one focusing on
etiology and the other on leaflet dysfunction, realizing that
both can influence patient outcome. For the purposes of this
discussion, we will focus on leaflet dysfunction as opposed
to etiology.33 This classification is based on the opening and
closing motions of the mitral leaflets. Patients with type I
dysfunction have normal leaflet motion. Mitral regurgitation
in these patients is due to annular dilatation or leaflet per-
2005
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type II dysfunction with the free edge of the leaflet over-
riding the plane of the annulus during systole (leaflet pro-
lapse). The most common lesions responsible for type II
dysfunction are chordal elongation or rupture and papillary
muscle elongation or rupture. Patients with type IIIa dys-
function have restricted leaflet motion during both diastole
and systole. The most common lesions are leaflet thicken-
ing/retraction, chordal thickening/shortening or fusion, and
commissural fusion. The mechanism of MR in type IIIb
dysfunction is restricted leaflet motion during systole: left
ventricular enlargement with apical papillary muscle dis-
placement due to ischemic or idiopathic cardiomyopathy
causes this type of valve dysfunction.
Currently, there are two concepts for percutaneous mitral
valve repair: 1) partial mitral annuloplasty by device place-
ment in the coronary sinus to reduce the circumference of
the posterior mitral annulus; and 2) anterior and posterior
leaflet attachment using an edge-to-edge clip or suture.44-46
Posterior annuloplasty faces multiple anatomic challenges
including dilation of the trigone-to-trigone area,47,48 leaflet
tethering by papillary muscle displacement,49 mitral annular
calcification, inability to fix the annuloplasty to the fibrous
trigones,50 and the potential for compromise of the circum-
flex coronary artery. The edge-to-edge repair concept has
been used in surgically treated patients, but the best results
have been obtained when combined with an annuloplasty.51
The results of edge-to-edge repair have been suboptimal in
patients with restricted leaflet motion (type III dysfunction),
including a recent surgical series where it was used in
combination with a posterior annuloplasty in patients with
ischemic regurgitation.52
A feasibility study designed to evaluate PMVR with
annular remodeling technology should consist of 20 to 30
patients with severe symptomatic MR caused by annular
dilation with normal leaflet motion (type I dysfunction) or
by restricted leaflet motion (type IIIb dysfunction), or by a
combination of these two mechanisms. A feasibility study
to evaluate PMVR with leaflet edge-to-edge repair should
consist of 20 to 30 patients with excessive leaflet motion
(type II dysfunction).
These studies will have safety as the primary end point
and will assess adverse events including residual (equal
or worse) MR, myocardial infarction, stroke, tamponade,
coronary artery injury, death, and leaflet damage com-
promising subsequent mitral valve repair. The secondary
end points of the study will include quantitative echocar-
diographic assessment of MR diminution, left ventricular
function, and symptom status. The design of Pivotal trials
will need to await safety and durability data from the
feasibility study, but will include: 1) comparison of
PMVR to open surgical mitral valve repair in patients
with types I, II, and IIIb dysfunction; or 2) comparison of
The Journal of ThoraciPMVR to optimal medical therapy53 in non-surgical can-
didates with either end-stage cardiomyopathy and type
IIIb severe MR or elderly patients with significant co-
morbidities and type II dysfunction.
Percutaneous Aortic Valve Replacement (PAVR)
Aortic valve replacement is the most common heart valve
operation. Aortic stenosis (AS) affects from 2% to 7% of
individuals older than 65 years in the U.S., a prevalence that
will continue to increase as more people live to older
ages.54,55 Aortic stenosis is consistently progressive,56-59
and because it occurs in an elderly age group it is often
associated with comorbid risk factors and previous bypass
surgery.60 The goals of therapy for patients with AS include
both improvement of symptoms and prolongation of life.61
Percutaneous strategies for the treatment of AS began with
percutaneous balloon valvuloplasty, but data from single-
center studies and the multicenter National Heart, Lung, and
Blood Institute (NHLBI) registry noted only a modest im-
provement in early hemodynamics, a substantial incidence
of peripheral vascular complications, a 30-day mortality of
7%, and a high incidence of restenosis within 6 months.7,62
The disappointing results of BAV have led to investiga-
tion of the possibility of percutaneous placement of pros-
thetic aortic valves. Such devices have been used clinically
in a small number of cases in high-risk patients.63 A feasi-
bility study designed to evaluate PAVR might consist of 20
to 30 patients with severe symptomatic AS (aortic valve
area 0.70 cm2), or severe aortic valve regurgitation (AR).
Initial feasibility trials have treated only AS patients be-
cause AR treatment is more problematic for the first gener-
ation of PAVR devices. Therefore, it is envisioned that
feasibility trials will initially enroll only patients with severe
AS.
In addition, differences in the age and comorbidity be-
tween patients with AS and AR dictate each study popula-
tion be fairly pure, with a cohort of one or the other but not
a mixture. These initial patients should be judged to be at
extremely high operative risk as calculated by an estab-
lished risk scoring system.64-67 Selection of a risk scoring
system as well as the definition of inoperability should be
clearly defined in the protocol. Such inoperability will al-
most always be caused by non-cardiac morbid conditions. In
such a feasibility trial it is not acceptable to use such devices
for patients who simply refuse open surgery on the basis of
personal preference. Study end points will include death,
stroke, myocardial infarction, para-prosthetic leak, device
migration, symptom status, angiographic gradient, and re-
hospitalization. Pivotal trials will depend upon the safety
data from the feasibility trial, and a variety of control groups
may be possible including patients having balloon valvulo-
plasty and high-risk open surgery.
c and Cardiovascular Surgery ● Volume 129, Number 5 973
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The procedural goal of PHVT is to reliably repair or replace
dysfunctional heart valves percutaneously and without the
need for cardiopulmonary bypass (CPB). An alternate ap-
proach has been to repair or replace valves off-pump
through small incisions, thereby simplifying device deliv-
ery. Concepts along these lines include anterior and poste-
rior pads connected by a subvalvular cord designed to draw
the posterior leaflet and annulus of the mitral valve toward
the anterior leaflet68; a transatrial off-pump edge-to-edge
mitral valve repair69; and off-pump AR antegrade through
the ascending aorta or retrograde through the left ventricular
apex.70 The minimally invasive surgical approach is an
avenue of treating heart valve disease that not only has
benefit on its own merit but also supports development of
PHVT.
Regulatory Considerations
At this Workshop, the general considerations of the FDA, as
expressed by Bram Zuckerman, Director of Cardiovascular
Devices, Office of Device Evaluation (ODE), Center for
Devices and Radiologic Health, were as follows. Percuta-
neous heart valve systems are considered class III devices;
they will be reviewed as pre-market approval (PMA) appli-
cations71 and, as such, controlled, randomized clinical trials
will be the gold standard for meeting FDA requirements.
Industry or independent study investigators should solicit
the assistance and guidance of the FDA before designing
any clinical trial for PHVT.72 Post-market approval studies
may be required.
Summary
Although percutaneous devices for the repair or replace-
ment of heart valves appear promising, they are clearly in an
early stage of development. Many critical questions remain
unanswered, including the durability of these devices and
the potential adverse effects they may have on subsequent
heart valve surgery. Therefore, one cannot justify the use of
these experimental technologies in patients for whom pub-
lished guideline indications do not exist or in situations of
prophylactic therapy until data on safety and effectiveness
are gathered from well-designed clinical trials. Study can-
didates should consist of symptomatic patients in whom
long-term survival is already severely compromised. Such a
strategy would allow the collection of mid-term device
durability data while providing much needed clinically rel-
evant safety and effectiveness data.
Prospective, randomized, clinical trials provide the most
reliable evidence of the effectiveness of the treatment. With-
out such trials, ineffective treatments (or worse, harmful
treatments) may be accepted in medical practice. Our col-
lective enthusiasm for new, less-invasive cardiovascular
approaches should not divert us from the importance of
974 The Journal of Thoracic and Cardiovascular Surgery ● Mayevaluating these devices in the context of a controlled
clinical trial environment. Success of these clinical trials
ultimately depends upon a sincere commitment to collabo-
ration between cardiology and cardiac surgery.
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